Antiplatelet antibody [7E3 F(ab')2] prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model
- PMID: 2105175
- DOI: 10.1161/01.cir.81.2.617
Antiplatelet antibody [7E3 F(ab')2] prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model
Abstract
Coronary artery rethrombosis can complicate initially effective thrombolytic therapy. Platelets interacting with injured vascular endothelium in a region along the coronary artery with reduced luminal cross-sectional area contribute to rethrombosis. The purpose of this study was to investigate the potential of the F(ab')2 fragment of the murine monoclonal antibody 7E3 [7E3 F(ab')2] to prevent rethrombosis after intracoronary clot lysis with recombinant tissue-type plasminogen activator (rt-PA) in an experimental model. The 7E3 F(ab')2 binds to the platelet glycoprotein IIb/IIIa complex (GPIIb/IIIa), thereby preventing platelet-fibrinogen interaction and intravascular thrombus formation. Experimental coronary artery thrombosis was produced in the anesthetized dog by application of direct anodal current to the intimal surface of the left circumflex coronary artery in the region of an external stenosis. Lysis of the established intracoronary thrombus was achieved with the intravenous administration of rt-PA (25 mg) after which the animals were randomized into two groups. Group 1 (n = 10) served as the control, receiving the saline diluent, and group 2 (n = 9) received 7E3 F(ab')2, given as a single intravenous injection (0.8 mg/kg). The times required for occlusive thrombus formation, rt-PA-induced thrombolysis, and rethrombosis (if it occurred) were similar in the animals treated with saline and those treated with 7E3 F(ab')2. The initial left circumflex coronary artery blood flow was similar in both groups but decreased to a negligible level in group 1. In group 2, left circumflex coronary artery blood flow declined modestly (24 +/- 2 to 10 +/- 2 ml/min). Rethrombosis occurred in all animals in group 1 but in only two of nine animals in group 2 (p less than 0.05). Oscillations in coronary blood flow preceded rethrombosis in group 1, whereas 7E3 F(ab')2 stabilized left circumflex coronary artery blood flow patterns during the course of teh experimental protocol (5.2 +/- 0.9 vs. 0.7 +/- 0.4 oscillations, respectively; p less than 0.05). Thrombus mass recovered from the left circumflex coronary artery at the conclusion of each experiment was greater in group 1 as compared with group 2 (7.0 +/- 2.3 vs. 1.5 +/- 0.7 mg, respectively; p less than 0.05). The area of left ventricle at risk for infarction was similar in both groups but infarct size, infarction/at risk assessed histochemically, was larger in group 1 than group 2 (35 +/- 9% vs. 6 +/- 4%, respectively; p less than 0.05). Platelet aggregation induced by ADP and arachidonic acid was similar at baseline for all of the animals.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
Antiplatelet monoclonal F(ab')2 antibody directed against the platelet GPIIb/IIIa receptor complex prevents coronary artery thrombosis in the canine heart.J Mol Cell Cardiol. 1989 Apr;21(4):393-405. doi: 10.1016/0022-2828(89)90650-0. J Mol Cell Cardiol. 1989. PMID: 2746660
-
Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. I. Adjunctive therapy with monoclonal antibody 7E3 F(ab')2 fragment.J Cardiovasc Pharmacol. 1994 Feb;23(2):194-202. J Cardiovasc Pharmacol. 1994. PMID: 7511747
-
Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody.J Am Coll Cardiol. 1990 Dec;16(7):1728-35. doi: 10.1016/0735-1097(90)90327-l. J Am Coll Cardiol. 1990. PMID: 2123910
-
[Antibody mediated thrombolysis. A new therapeutic principle].Klin Wochenschr. 1989 Jul 3;67(13):651-8. doi: 10.1007/BF01718025. Klin Wochenschr. 1989. PMID: 2502649 Review. German.
-
Low-Dose Slow Infusion Tissue Plasminogen Activator (tPA) in Treatment of Thrombotic Coronary Artery Occlusions: Case Series and Literature Review.Anatol J Cardiol. 2022 Apr;26(4):249-257. doi: 10.5152/AnatolJCardiol.2022.1083. Anatol J Cardiol. 2022. PMID: 35435835 Free PMC article. Review.
Cited by
-
Systemic lysis protects against the effects of platelet activation during coronary thrombolysis.J Clin Invest. 1991 Nov;88(5):1589-95. doi: 10.1172/JCI115471. J Clin Invest. 1991. PMID: 1939647 Free PMC article.
-
Integrins.J Clin Invest. 1991 Jan;87(1):1-5. doi: 10.1172/JCI114957. J Clin Invest. 1991. PMID: 1985087 Free PMC article. Review. No abstract available.
-
Prevention of thrombosis and rethrombosis and enhancement of the thrombolytic actions of recombinant tissue-type plasminogen activator in the canine heart by DMP728, a glycoprotein IIb/IIIa antagonist.Br J Pharmacol. 1994 Dec;113(4):1333-43. doi: 10.1111/j.1476-5381.1994.tb17144.x. Br J Pharmacol. 1994. PMID: 7889289 Free PMC article.
-
Prevention of experimental carotid and coronary artery thrombosis by the glycoprotein IIb/IIIa receptor antagonist CRL42796.Br J Pharmacol. 2002 Jul;136(6):927-37. doi: 10.1038/sj.bjp.0704744. Br J Pharmacol. 2002. PMID: 12110617 Free PMC article.
-
Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease.Drugs. 1994 Oct;48(4):583-98. doi: 10.2165/00003495-199448040-00007. Drugs. 1994. PMID: 7528131 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources